SVB Securities

Disc Medicine Announces Underwritten Offering of Common Stock

Retrieved on: 
金曜日, 6月 14, 2024
Janus, Prospectus, SVB Securities, Patient, Research, Atlas Venture, Security (finance), Form S-3, Attention, OrbiMed, State Street, Form, Sale, Wellington Management Company, Paradigm, Disc, IRON

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share.

Key Points: 
  • WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share.
  • The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0 million, before deducting underwriting discounts and commissions and other offering expenses.
  • All of the securities being sold in the offering are being offered by Disc.
  • The offering is expected to close on June 17, 2024, subject to the satisfaction of customary closing conditions.

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Retrieved on: 
金曜日, 6月 14, 2024
Janus, Capital market, Prospectus, SVB Securities, American depositary receipt, Telephone, Security (finance), Madison Avenue, Attention, ADS, State Street, Form, Jefferies Group, Sale, Cantor

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”).

Key Points: 
  • LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”).
  • Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million.
  • The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.

Replimune Announces $100 Million Private Placement Financing

Retrieved on: 
木曜日, 6月 13, 2024
Prospectus, SVB Securities, Exercise, PIPE, RP1, BLA, United, Investment, Skin, Sale, Common stock, Security (finance)

WOBURN, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) that is expected to result in gross proceeds of approximately $100 million to the Company before deducting placement agent fees and offering expenses. The financing was led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors, including a leading mutual fund.

Key Points: 
  • The financing was led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors, including a leading mutual fund.
  • The financing is expected to close on or about June 14, 2024, subject to satisfaction of customary closing conditions.
  • Leerink Partners acted as sole placement agent for the PIPE financing.
  • Any offering of the common stock under the resale registration statement will only be made by means of prospectus.

LifeSci Capital Announces Senior Appointments of Mikhail Keyserman CMT CFTe and Jared Sender MD MBA to Strengthen Investment Banking Team

Retrieved on: 
月曜日, 6月 10, 2024
SVB Securities, Communication, MBA, MD, Executive officer, Silicon, SUNY Downstate Medical Center, Record, University, Health, Merrill (company), Payment, Management consulting, NYU, Brandeis University, CMT, Research, Population health, Hospital, Business, Fidelis Care, Health care, Citigroup, Partner, Research fellow, Therapy, Management

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- LifeSci Capital LLC, a research-driven investment bank focused on the life sciences, today announces the expansion of its investment banking team with the appointments of Mikhail Keyserman, CMT CFTe, and Jared Sender, MD MBA, as Managing Directors.

Key Points: 
  • NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- LifeSci Capital LLC, a research-driven investment bank focused on the life sciences, today announces the expansion of its investment banking team with the appointments of Mikhail Keyserman, CMT CFTe, and Jared Sender, MD MBA, as Managing Directors.
  • Mr. Keyserman and Dr. Sender were recently Managing Directors in Investment Banking at BTIG.
  • The appointments of Mr. Keyserman and Dr. Sender underscore LifeSci Capital's commitment to excellence and meaningful relationships in life sciences and healthcare investment banking.
  • LifeSci leverages global relationships and local knowledge in multiple territories around the world to provide high-value services for clients.

Permira Announces Substantial Investment in PharmaCord

Retrieved on: 
木曜日, 6月 6, 2024
Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Slate, SVB Securities, Organization, Centerview Partners, Growth, LLP, Jefferies Group, Willkie Farr & Gallagher, Pharmaceutical industry

Permira, the global investment firm, and PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the pharmaceutical industry, today announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord.

Key Points: 
  • Permira, the global investment firm, and PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the pharmaceutical industry, today announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord.
  • Founder and Chief Executive Officer Nitin Sahney and the management team will continue to lead PharmaCord and will remain significant investors in the Company alongside the Permira funds.
  • “We are very excited to partner with a leading, growth-oriented, technology-focused investment firm like Permira to help us broaden our tech-enabled offerings and support our ambitious expansion efforts,” said Nitin Sahney, Founder and CEO of PharmaCord.
  • Jefferies LLC and Leerink Partners acted as financial advisors to Permira and Skadden, Arps, Slate, Meagher & Flom LLP acted as Permira’s legal counsel.

Bionomics Limited Announces Private Placement of up to $70.0 Million

Retrieved on: 
金曜日, 5月 31, 2024
Patient, Exchange, Food, BNC210, Exercise, PTSD, Sale, ADS, American depositary receipt, Prospectus, Research, SVB Securities, Public expenditure, Central nervous system, Security (finance)

The first tranche is an upfront payment to the Company of $7.5 million.

Key Points: 
  • The first tranche is an upfront payment to the Company of $7.5 million.
  • Assuming that the first, second and third tranches are consummated and exercised to the maximum extent, total gross proceeds from the private placement to the Company would be approximately $70.0 million.
  • The private placement is expected to close on or about June 3, 2024, subject to the satisfaction of customary closing conditions.
  • The Company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission registering the resale of the securities issued and issuable in the private placement.

Celcuity Announces Pricing of Underwritten Common Stock Offering

Retrieved on: 
木曜日, 5月 30, 2024
Patient, Fulvestrant, CELC, Investment, Suite, Telephone, Sale, Breast cancer, Form, Prospectus, Research, Attention, Vanderbilt Avenue, SVB Securities, Richard Driehaus, State Street, Public expenditure, Clinical trial, Montgomery Street, Security (finance)

MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share.

Key Points: 
  • MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share.
  • The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions.
  • Gross proceeds to Celcuity from the offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and offering expenses.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Merus Announces Pricing of Upsized Public Offering of Common Shares

Retrieved on: 
木曜日, 5月 30, 2024
Investment, Jefferies, EEA, BMO Capital Markets, Form, Attention, Madison Avenue, BofA Securities, European Economic Area, Telephone, Sale, Communication, Security (finance), Finance, Advertising, Jefferies Group, S-3, SVB Securities, State Street, FSMA, Person, Floor, Prospectus, Guggenheim Partners, File

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).
  • Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • All of the shares in the offering are to be sold by Merus.
  • Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.

Merus N.V. Announces Proposed Public Offering of Common Shares

Retrieved on: 
火曜日, 5月 28, 2024
Investment, Jefferies, EEA, BMO Capital Markets, Form, Attention, Madison Avenue, BofA Securities, European Economic Area, Telephone, Sale, Communication, Security (finance), Finance, Advertising, Jefferies Group, S-3, SVB Securities, State Street, FSMA, Person, Floor, Prospectus, Guggenheim Partners, File

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”).
  • All of the common shares are being offered by Merus.
  • In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.

Owens & Minor to Present at the Leerink Partners’ Healthcare Crossroads Conference on May 29, 2024

Retrieved on: 
火曜日, 5月 28, 2024
Medical Supplies, Health, Communications, Hospitals, Managed Care, General Health, Public Relations, Investor Relations, Conference, Owens & Minor, SVB Securities, OMI

Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas.

Key Points: 
  • Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas.
  • Owens & Minor is also hosting one-on-one meetings with investors at the conference.
  • Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations at least 10 minutes in advance to register for the live webcast of the discussion.